Zobrazeno 1 - 5
of 5
pro vyhledávání: '"M P van Herk-Sukel"'
Autor:
E P de Feyter, Huub A.A.M. Maas, R W Vingerhoets, M P van Herk-Sukel, Valery E.P.P. Lemmens, David D. E. Zimmerman, F.N. van Erning, M E van de Poll, JG Kuiper, M.M.J. Zanders
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics, 41(5), 538-545. Wiley-Blackwell
Journal of Clinical Pharmacy and Therapeutics, 41(5), 538-545. Wiley-Blackwell Publishing Ltd
Journal of Clinical Pharmacy and Therapeutics, 41(5), 538. Wiley-Blackwell
Journal of Clinical Pharmacy and Therapeutics, 41(5), 538-545. Wiley-Blackwell Publishing Ltd
Journal of Clinical Pharmacy and Therapeutics, 41(5), 538. Wiley-Blackwell
WHAT IS KNOWN AND OBJECTIVE: The concomitant use of multiple drugs is common among the general population of elderly. The aim of this study was to provide an overview of which drugs are dispensed to elderly in the year before colon cancer diagnosis a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b1615cf221ee4bc7f85ee8f9c8298a
https://doi.org/10.1111/jcpt.12434
https://doi.org/10.1111/jcpt.12434
Autor:
D E, Issa, H, Gelderblom, P J, Lugtenburg, M P, van Herk-Sukel, L M A, Houweling, M, De La Orden, M E, van der Werf-Langenberg, J W R, Nortier, F A, de Jong
Publikováno v:
European journal of cancer care. 24(2)
Few data have been published on healthcare resource utilisation associated with chemotherapy-induced febrile neutropenia (FN) in Europe. Using the PHARMO record linkage system, we identified incident adult patients with a primary hospital discharge d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::35cf65e0432060c05fc856540ed13339
https://pubmed.ncbi.nlm.nih.gov/24528512
https://pubmed.ncbi.nlm.nih.gov/24528512
Autor:
Valery E.P.P. Lemmens, M E van de Poll, JG Kuiper, David D. E. Zimmerman, F.N. van Erning, R W Vingerhoets, M.M.J. Zanders, E P de Feyter, M P van Herk-Sukel, Huub A.A.M. Maas
Publikováno v:
Journal of Geriatric Oncology. 5:S38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b7d8085210578f96ec9a5433a6523ea
https://doi.org/10.1016/j.jgo.2014.09.060
https://doi.org/10.1016/j.jgo.2014.09.060
Autor:
V. Dezentje, N. J. Van Blijderveen, H. Gelderblom, H. Putter, M. P. Van Herk-Sukel, M. K. Casparie, A. C. Egberts, J. W. Nortier, H. J. Guchelaar
Publikováno v:
Journal of Clinical Oncology. 27:CRA509-CRA509
CRA509 Background: The use of cytochrome P450 2D6 inhibiting drugs (CYP2D6 inhibitors) during tamoxifen treatment leads to a decrease in plasma concentration of endoxifen, the major active tamoxifen metabolite. Concomitant use of CYP2D6 inhibitors, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a31a147314040f7a11339890c42b55b
https://doi.org/10.1200/jco.2009.27.18_suppl.cra509
https://doi.org/10.1200/jco.2009.27.18_suppl.cra509
Autor:
Mariel K. Casparie, N. J. Van Blijderveen, Antoine C. G. Egberts, J.W.R. Nortier, Hein Putter, H-J Guchelaar, M. P. Van Herk-Sukel, Hans Gelderblom, Vincent O. Dezentjé
Publikováno v:
Journal of Clinical Oncology. 27:CRA509-CRA509
CRA509 Background: The use of cytochrome P450 2D6 inhibiting drugs (CYP2D6 inhibitors) during tamoxifen treatment leads to a decrease in plasma concentration of endoxifen, the major active tamoxifen metabolite. Concomitant use of CYP2D6 inhibitors, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f33046e335f3dd30cb7524d5f5ac42a0
https://doi.org/10.1200/jco.2009.27.15_suppl.cra509
https://doi.org/10.1200/jco.2009.27.15_suppl.cra509